Conduit Pharmaceuticals Stock Shares Owned By Insiders
| CDT Stock | 0.88 0.05 5.84% |
Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.
Conduit | Shares Owned By Insiders |
Conduit Pharmaceuticals Company Shares Owned By Insiders Analysis
Conduit Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Conduit Pharmaceuticals Shares Owned By Insiders | 13.92 % |
Most of Conduit Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Conduit Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Conduit Pharmaceuticals is extremely important. It helps to project a fair market value of Conduit Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Conduit Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Conduit Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Conduit Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 13.92% of Conduit Pharmaceuticals are shares owned by insiders. This is 8.3% lower than that of the Life Sciences Tools & Services sector and about the same as Health Care (which currently averages 14.18) industry. The shares owned by insiders for all United States stocks is 37.96% lower than that of the firm.
Conduit Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.Conduit Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Conduit Fundamentals
| Return On Asset | -1.09 | ||||
| Current Valuation | 7.6 M | ||||
| Shares Outstanding | 6.2 M | ||||
| Shares Owned By Insiders | 13.92 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 562.28 K | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B | ||||
| Book Value Per Share | (9.50) X | ||||
| Cash Flow From Operations | 344.8 M | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (23.00) X | ||||
| Beta | 2.27 | ||||
| Market Capitalization | 5.12 M | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 1.18 B | ||||
| Working Capital | 3.93 M | ||||
| Net Asset | 3.26 B |
About Conduit Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.